---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349170"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2026-08-13T20:08:48+00:00"
generated_at: "2026-08-13T20:11:22.914804+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eledon Q2 net loss $31.6M; cash $88.8M; Phase 3 kidney trial on track

## Summary
- Cash $88.8M at June 30, 2026 vs $133.3M at Dec 31, 2025; expected to fund ops into Q2 2027.
- Q2 net loss $31.6M ($0.27/share) vs $11.2M ($0.13) prior year; ex-warrant changes, loss $22.0M vs $23.5M.
- FDA End-of-Phase 2 meeting supports Phase 3 kidney transplant trial of tegoprubart; ~600 patients, late 2026 start.
- BESTOW 18-month data: eGFR ~12 mL/min higher vs tacrolimus (74 vs 61); no BPAR after 6 months in tegoprubart arm.
- Islet cell study: all 12 T1D patients insulin-independent, mean HbA1c ~5.4%; Natera Prospera partnership for Phase 3.

## SEC filing metadata
- accession: 0001193125-26-349170
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2026-08-13T20:08:48+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/0001193125-26-349170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000119312526349170/eldn-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349170
- JSON: https://secwatch.observer/filing/0001193125-26-349170.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.